Trial intelligence / Profile preview

Adjuvant toripalimab + capecitabine versus capecitabine alone after R0 resection for intrahepatic cholangiocarcinoma

ChiCTR2000036630Phase 2Not yet recruiting

Sponsor
Third Affiliated Hospital of Naval Medical University
Start
Oct 2020
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 2, randomised, open-label trial in intrahepatic cholangiocarcinoma (ICC) comparing Toripalimab + capecitabine with Capecitabine (2 arms). Primary endpoint: recurrence-free survival. Planned start Oct 2020; status: not yet recruiting.

02

Drugs

toripalimabcapecitabine
03

Conditions

intrahepatic cholangiocarcinoma (ICC)

Beyond the preview

Go deeper on ChiCTR2000036630.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR2000036630.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call